Can-Fite To Initiate Phase I/II Hepatitis C Trial
Can-Fite is going to initiate phase I/II clinical trial with CF102 for the treatment of Hepatitis C Virus (HCV), following the approval by the Israel Ministry of Health
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).